Quince Therapeutics, Inc. (QNCX)

Market Cap	41.84M
Revenue (ttm)	n/a
Net Income (ttm)	-30.60M
Shares Out	36.38M
EPS (ttm)	-0.83
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	566
Open	1.15
Previous Close	1.15
Day's Range	1.13 - 1.19
52-Week Range	0.54 - 1.93
Beta	1.31
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2023

About QNCX

Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 9, 2019
• Employees: 21
• Stock Exchange: NASDAQ
• Ticker Symbol: QNCX